RARX - Ra Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
2.21B
Enterprise Value 3
1.92B
Trailing P/E
N/A
Forward P/E 1
-18.79
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
401.00
Price/Book (mrq)
7.50
Enterprise Value/Revenue 3
348.59
Enterprise Value/EBITDA 6
-22.88

Trading Information

Stock Price History

Beta (5Y Monthly) 1.46
52-Week Change 3143.94%
S&P500 52-Week Change 325.78%
52 Week High 347.55
52 Week Low 318.06
50-Day Moving Average 346.97
200-Day Moving Average 338.25

Share Statistics

Avg Vol (3 month) 3720.36k
Avg Vol (10 day) 3650.97k
Shares Outstanding 547.15M
Float 35.72M
% Held by Insiders 14.05%
% Held by Institutions 193.63%
Shares Short (Dec 30, 2019) 45.49M
Short Ratio (Dec 30, 2019) 48.8
Short % of Float (Dec 30, 2019) 415.28%
Short % of Shares Outstanding (Dec 30, 2019) 411.64%
Shares Short (prior month Nov 28, 2019) 44.1M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-1,560.18%

Management Effectiveness

Return on Assets (ttm)-26.84%
Return on Equity (ttm)-43.88%

Income Statement

Revenue (ttm)5.5M
Revenue Per Share (ttm)0.13
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)2.5M
EBITDA -83.79M
Net Income Avi to Common (ttm)-82.11M
Diluted EPS (ttm)-2.00
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)292.6M
Total Cash Per Share (mrq)6.21
Total Debt (mrq)4.48M
Total Debt/Equity (mrq)1.52
Current Ratio (mrq)25.73
Book Value Per Share (mrq)6.24

Cash Flow Statement

Operating Cash Flow (ttm)-70.82M
Levered Free Cash Flow (ttm)-42.59M